Intellia Therapeutics Reports Q1 Results, Extends Cash Runway to 2028 with $207M Offering Proceeds

summarizeSummary

Intellia Therapeutics reported Q1 2026 financial results, highlighting a reduced net loss and an extended cash runway into 2028, bolstered by a recent $207 million public offering.

check_boxKey Events

• Q1 2026 Financial Results

  Reported a net loss of $96.2 million for Q1 2026, an improvement from $114.3 million in Q1 2025, driven by reduced R&D expenses.

• Extended Cash Runway

  Proceeds from the April 2026 public offering, totaling approximately $207 million, are expected to fund operations at least into 2028, extending the previous guidance of the second half of 2027.

• Lonvo-z Regulatory Progress

  Initiated a rolling Biologics License Application (BLA) submission to the FDA for lonvo-z in Hereditary Angioedema (HAE), targeting a U.S. launch in the first half of 2027.

• Nex-z Clinical Trial Resumption

  Patient screening has resumed for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for ATTR amyloidosis, following the FDA lifting clinical holds.

auto_awesomeAnalysis

Intellia Therapeutics' first-quarter results show a reduced net loss and R&D expenses. Critically, the company confirmed that proceeds from its recent $207 million public offering have extended its cash runway into at least 2028, providing significant financial stability for its ongoing clinical programs, including the rolling BLA submission for lonvo-z and resumed Phase 3 trials for nex-z. This extended runway is a key positive for a clinical-stage biotech.